Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

oleh: Dominiek Smeets, Ian S. Miller, Darran P. O’Connor, Sudipto Das, Bruce Moran, Bram Boeckx, Timo Gaiser, Johannes Betge, Ana Barat, Rut Klinger, Nicole C. T. van Grieken, Chiara Cremolini, Hans Prenen, Massimiliano Mazzone, Jeroen Depreeuw, Orna Bacon, Bozena Fender, Joseph Brady, Bryan T. Hennessy, Deborah A. McNamara, Elaine Kay, Henk M. Verheul, Neerincx Maarten, William M. Gallagher, Verena Murphy, Jochen H. M. Prehn, Miriam Koopman, Cornelis J. A. Punt, Fotios Loupakis, Matthias P. A. Ebert, Bauke Ylstra, Diether Lambrechts, Annette T. Byrne

Format: Article
Diterbitkan: Nature Portfolio 2018-10-01

Deskripsi

Increased copy number alterations, indicative of chromosomal instability, is associated with poor cancer outcome. Here, metastatic colorectal cancer patients displaying intermediate-high CIN associate with improved outcome following chemotherapy and bevacizumab treatment, suggesting CIN as a predictive biomarker.